Radiopharm Theranostics (ASX: RAD, NASDAQ: RADX) has begun enrolling patients in the third cohort of its Phase 1 dose escalation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE